Florida man shot point-blank in chest saved by cross pendant
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors
New board members bring decades of experience in company building, corporate strategy, drug development, and commercialization across multiple therapeutic areas CAMBRIDGE, Mass., August 19, 2025--(BUSINESS WIRE)--eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the appointment of Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors. Douglas Williams, Ph.D., brings more than 30 years of leadership experience in the biopharmaceutical industry, including senior executive roles at Biogen, ZymoGenetics, Amgen, and Seattle Genetics (now Seagen). He has contributed to the development of several blockbuster therapies, including Enbrel®, Tecfidera® and Spinraza®. Most recently, he served as President of R&D at Sana Biotechnology and as founding CEO of Codiak Biosciences. Dr. Williams currently serves on the boards of Climb Bio (Chair) and CAMP4 Therapeutics. Adam Craig, M.D., Ph.D., is a biotechnology executive with over 25 years of global experience in drug development and commercialization, particularly in oncology, hematology, and rare diseases. He served as President and CEO of CTI BioPharma leading to the approval and commercialization of Vonjo®. He is currently Executive Chairman of X4 Pharmaceuticals and was recently interim CEO of Stratus Therapeutics (formerly Garuda Therapeutics). Dr Craig previously held CMO and senior development roles at Sunesis Pharmaceuticals and Chemgenex Pharmaceuticals and currently serves on the board of Stratus Therapeutics. Dr. Craig is a Member of the Royal College of Physicians (U.K.) and holds medical and doctoral degrees from the University of London, a Ph.D. in Molecular Oncology from Leeds University, and an MBA from the Open Business School. "Doug and Adam are highly accomplished leaders whose deep expertise across R&D, commercialization, and corporate strategy will be invaluable as we advance our development candidates, EGEN-2784 for kidney failure and EGEN-5784 for liver failure, into the clinic," said Michael Curtis, Ph.D., Chief Executive Officer, eGenesis. "Their guidance will be invaluable as we advance into the next phase of growth as a clinical-stage company focused on our mission to transform the treatment of organ failure." "eGenesis is developing truly pioneering solutions for one of the most pressing unmet needs in medicine," said Dr. Williams. "The combination of cutting-edge genetic engineering, rigorous science, and a mission-driven team positions eGenesis to deliver breakthroughs that could fundamentally change the field of organ transplantation." "eGenesis is leading a field with the potential to transform the future of transplantation," added Dr. Craig. "I look forward to supporting the company's mission to develop safe, effective, human-compatible organs that could redefine the treatment of organ failure and offer hope to millions of patients awaiting a transplant." Drs. Williams and Craig join current Board members Steven Gillis, Ph.D. (Board Chairman), Bob More, Fabio Pucci, Ph.D., Brad Smith, Julie Sunderland, and Albert (Al) Wiegman. About eGenesis eGenesis is pioneering a genome engineering-based approach to develop safe, effective transplantable organs to end the global organ shortage. Its platform uniquely addresses cross-species molecular incompatibilities and viral risk via its proprietary genetic engineering platform to improve outcomes for patients in need of a transplant. With demonstrated preclinical success, eGenesis is advancing programs in kidney transplantation, acute liver failure, and heart transplantation. Learn more at Follow us @egenesisbio. View source version on Contacts MediaKimberly Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution
SOUTH SAN FRANCISCO, Calif., August 19, 2025--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research. "We designed this panel to break the status quo in genomic profiling by offering laboratories a powerful alternative to locked, one-size-fits-all solutions," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "With our customizable content, flexible workflow, and compatibility with multiple sequencing platforms, Twist's Oncology DNA CGP Panel puts scientific control back in the hands of researchers and clinicians, particularly for those who need a more cost-effective solution compared to existing CGP products or a more efficient option than smaller panels." The Twist Oncology DNA CGP Panel was designed to serve a wide range of research groups including regional clinical labs, academic medical centers, and biopharma partners. The panel composition incorporates clinical research and includes a comprehensive and updated biomarker list covering 562 genes that incorporate all major tumor types. The panel's coverage spans genomic alterations and genomic signatures and can detect base substitutions, insertions and deletions (indels), copy number variations (CNVs), gene rearrangements as well as measure tumor mutational burden (TMB) and microsatellite instability (MSI). This is paired with Twist high quality and easy-to-use library preparation and target enrichment workflows. Twist is collaborating with several analytics companies to provide a complete solution from sequencing to analysis. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky Twist Bioscience Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about the expected future benefits and impact of the Twist Oncology DNA CGP Panel and collaborations with analytics companies. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. View source version on Contacts For Investors: Angela BittingSVP, Corporate Affairs925-202-6211abitting@ For Media: Amanda HoulihanCommunications Manager774-265-5334ahoulihan@
Fast Company
27 minutes ago
- Fast Company
Healthcare docs are the unsung hero of travel season: An estate planning expert and seasoned traveler weighs in
If you've ever felt that jolt of anxiety mid-flight—the kind that hits during unexpected turbulence—you're not alone. I've logged more than 350 flights since founding Trust & Will, and even as a seasoned traveler, there are still moments that shake me. It turns out, I'm not the only one who thinks about mortality somewhere over 30,000 feet. Since launching our estate planning platform in 2017, we've consistently seen a spike in new members and updates to plans right before major holidays and travel weekends. Every July, without fail, we get messages from parents on their way to Europe, newlyweds prepping for a honeymoon, or college grads heading out on post-grad adventures, many of whom start or finish their estate plan in the final hours before boarding. Why? Because travel is a trigger. Not just for excitement, but for reflection—and a little fear. THE OVERLOOKED MVP OF YOUR ESTATE PLAN When most people think about estate planning, they picture a will. Maybe a trust. Maybe funeral wishes. But one of the most important sets of documents often gets overlooked—especially by younger people: healthcare documents. These include your HIPAA authorization, medical power of attorney, and living will (also known as an advance healthcare directive). Collectively, they determine who can speak on your behalf, access your medical info, and make decisions if you're unable to. In other words: They're the playbook for your care when the unexpected happens. DESIGN MEETS INTENTION An estate plan should be frictionless, intuitive, and human. The same design principles that guide app UX or airline check-in flows apply here. The process of choosing a healthcare proxy or outlining medical preferences should feel approachable, not anxiety-inducing. That's why we spent years developing a guided experience that walks people through decisions in plain language. Whether you're sitting at a gate or on a layover, your documents are a tap away and ready to be shared if you're ever in an emergency, especially in rural or international areas where access to care is different. We've heard real stories: A hiking injury in Maui where a traveler needed emergency airlift and care coordination. A solo trip to Europe where a college student got sick and had no legal guardian anymore, but hadn't yet appointed a healthcare agent. These aren't just hypotheticals; they're avoidable moments of chaos if the right documents are in place. QUICK TIPS BEFORE YOUR NEXT TRIP Whether you're a frequent flyer or just headed out for summer vacation, here are three things to do before your next takeoff: Name A Healthcare Proxy: Who do you trust to speak on your behalf if you're unconscious or unable to communicate? This isn't just for the elderly—it's crucial for everyone over 18. Store Your Documents Digitally: Paper is great until you leave it in a hotel drawer. Keep digital copies of your estate and health documents in a secure vault or cloud platform that you can access and share from anywhere. Talk To Your Travel Companions: It might feel awkward, but telling your spouse, partner, or travel buddy where your documents are stored and what your wishes are can make a huge difference in an emergency. A DIFFERENT KIND OF TRAVEL CHECKLIST In the same way you wouldn't travel without your ID or passport, your estate plan—especially your healthcare documents—deserves a spot on your checklist. We spend a lot of time planning our vacations. Booking the right hotel. Earning points for upgrades. Picking restaurants. But the true peace of mind? It doesn't come from TSA PreCheck or an airport lounge. It comes from knowing that if something were to happen, your family isn't left scrambling for answers. That kind of planning? It's the ultimate design of care.
